Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH-1028 in locally advanced or metastatic NSCLC
NCT03823807Phase 2Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03823807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823807.